Full Press Release Details
Jurisdictions Continue to Recognize Microbot Medical's Innovative Technology; Receives Notice of Allowance for a U.S. Patent
Covering its TipCAT Technology Platform
Mass., Nov. 25, 2019 - Further demonstrating its commitment to expand and protect its Intellectual Property (IP) portfolio,
Microbot Medical Inc. (Nasdaq: MBOT) was issued a Notice of Allowance for patent application No. 15/936,878 by the U.S. Patent
and Trademark Office (USPTO). The allowed patent application covers the Company's TipCATTM technology platform.
we near the expected FDA pre-submission for our first product, the Self Cleaning Shunt (SCSTM), we have also experienced
an acceleration in the expansion of our patent estate - with this latest allowance being the 5th to date in 2019
and across several global jurisdictions, including North America and Europe," said Harel Gadot, Chief Executive Officer,
President, and Chairman. "As we identify and pursue future product offerings in the fast-growing, minimally invasive surgical
robotics market, protecting our assets and creating formidable barriers to entry through a proactive and effective global patent
portfolio strategy is fundamental to building value for our shareholders and other stakeholders."
allowed patent application is a Continuation of Patent No. 9,937,326, issued on April 10, 2018, which is a Continuation of Patent
No. 9,061,118, issued on June 23, 2015. It covers a self-propelled device for locomotion through a lumen, the device comprising
a set of serially arranged inflatable chambers configured for sequential inflation from a single fluid source, wherein the outer
skin of at least one of the chambers has at least one longitudinal section of greater rigidity than other sections of the outer
skin, such that when that chamber inflates, the set of chambers transitions to a bent state.
the Company now has 35 patents issued/allowed and 16 patent applications pending worldwide.
Microbot Medical, Inc.
specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human
body. Microbot's current technological platforms, ViRobTM, TipCATTM and CardioSertTM, are
comprised of three highly advanced technologies, from which the Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or SCSTM, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. The Company
also is focused on the development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information
about Microbot Medical is available at http://www.microbotmedical.com.
ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRobTM please visit
is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see & treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCATTM,
technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSertTM technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSertTM was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not
limited to statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization
of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty
in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses
of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.'s filings
with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking